Announcements Trials

Browse Landscape

Phase

Phase 2 30 Phase 1 12 Phase 1/2 11 Phase EARLY_PHASE1 3 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 40 Dermatologic 26 Genitourinary 23 Gastrointestinal 22 Head & Neck 10 CNS 6 Other solid neoplasm 5 Lymphoid 3 Gynecologic 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Breast 1

Conditions

Interventions

Doxorubicin 40 Radiotherapy 30 Ifosfamide 28 Vincristine 27 Cyclophosphamide 24 Imatinib Mesylate 20 Etoposide 20 Dactinomycin 14 Radiation 13 Filgrastim 11 Temozolomide 9 Sunitinib 9 Trabectedin 8 Methotrexate 8 Specimen Handling 7 Magnetic Resonance Spectroscopy 6 Granulocyte Colony-Stimulating Factor 6 Chemotherapy, Adjuvant 6 pazopanib 5 nilotinib 5 Zoledronic Acid 5 Neoadjuvant Therapy 5 Irinotecan 5 Cisplatin 5 Carboplatin 5 X-Rays 4 Vinorelbine 4 Topotecan 4 Surgical Procedures, Operative 4 Procarbazine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Nivolumab × Sarcoma × Clear all

NCT04741438 2023-08-30

RAR-Immune

Centre Leon Berard

Phase 3 Unknown

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡